These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1634926)

  • 21. Dosing of thioTEPA for myeloablative therapy.
    Przepiorka D; Madden T; Ippoliti C; Estrov Z; Dimopoulos M
    Cancer Chemother Pharmacol; 1995; 37(1-2):155-60. PubMed ID: 7497586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adriamycin, bleomycin and vincristine chemotherapy with recombinant granulocyte-macrophage colony-stimulating factor in the treatment of AIDS-related Kaposi's sarcoma.
    Gill PS; Bernstein-Singer M; Espina BM; Rarick M; Magy F; Montgomery T; Berry MS; Levine A
    AIDS; 1992 Dec; 6(12):1477-81. PubMed ID: 1283520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial.
    Vose JM; Pandite AN; Beveridge RA; Geller RB; Schuster MW; Anderson JE; LeMaistre CF; Ahmed T; Granena A; Keating A; Fernandez Ranada JM; Stiff PJ; Tabbara I; Longo W; Copelan EA; Nichols C; Smith A; Topolsky DL; Bierman PJ; Lebsack ME; Lange M; Garrison L
    J Clin Oncol; 1997 Apr; 15(4):1617-23. PubMed ID: 9193361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation.
    Gordon B; Spadinger A; Hodges E; Ruby E; Stanley R; Coccia P
    J Clin Oncol; 1994 Sep; 12(9):1917-22. PubMed ID: 7916041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.
    Tepler I; Cannistra SA; Frei E; Gonin R; Anderson KC; Demetri G; Niloff J; Goodman H; Muntz H; Muto M
    J Clin Oncol; 1993 Aug; 11(8):1583-91. PubMed ID: 8101563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial.
    Bernstein SH; Christiansen NP; Fay JP; Brown R; Herzig R; Frankel S; Blumenson L; Herzig GP
    Exp Hematol; 1996 Oct; 24(12):1363-8. PubMed ID: 8913281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil.
    O'Reilly SE; Gelmon KA; Onetto N; Parente J; Rubinger M; Page RA; Plenderleith IH
    J Clin Oncol; 1993 Dec; 11(12):2411-6. PubMed ID: 8246030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia.
    Kurzrock R; Talpaz M; Gutterman JU
    Am J Med; 1992 Jul; 93(1):41-8. PubMed ID: 1626572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy.
    Wexler LH; Weaver-McClure L; Steinberg SM; Jacobson J; Jarosinski P; Avila N; Pizzo PA; Horowitz ME
    J Clin Oncol; 1996 Mar; 14(3):901-10. PubMed ID: 8622038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma.
    Moreau P; Fiere D; Bezwoda WR; Facon T; Attal M; Laporte JP; Colombat P; Haak HL; Monconduit M; Lockhorst H; Girault D; Harousseau JL
    J Clin Oncol; 1997 Feb; 15(2):660-6. PubMed ID: 9053491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose escalation of N,N',N"-triethylenethiophosphoramide combined with pentoxifylline for advanced breast cancer.
    Shapiro CL; Dezube BJ; Tretyakov O; Wright J; Cap B; Henderson IC; Hayes DF
    Clin Cancer Res; 1995 Aug; 1(8):791-6. PubMed ID: 9816047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mobilization of peripheral blood stem cells by subcutaneous injections of yeast-derived granulocyte macrophage colony stimulating factor: a phase I-II study.
    Mangan K; Mullaney M; Klumpp T; Goldberg S; Macdonald J
    Stem Cells; 1993 Sep; 11(5):445-54. PubMed ID: 8241955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma.
    Gianni AM; Bregni M; Siena S; Orazi A; Stern AC; Gandola L; Bonadonna G
    J Clin Oncol; 1990 May; 8(5):768-78. PubMed ID: 2185337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer.
    Steward WP; Scarffe JH; Dirix LY; Chang J; Radford JA; Bonnem E; Crowther D
    Br J Cancer; 1990 May; 61(5):749-54. PubMed ID: 1692472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation.
    Greenberg P; Advani R; Keating A; Gulati SC; Nimer S; Champlin R; Karanes C; Gorin NC; Powles RL; Smith A; Lamborn K; Cuffie C
    Bone Marrow Transplant; 1996 Dec; 18(6):1057-64. PubMed ID: 8971373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies.
    Schiller JH; Storer B; Arzoomanian R; Tutsch K; Alberti D; Spriggs D
    Invest New Drugs; 1993 Nov; 11(4):291-300. PubMed ID: 8157471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer.
    Reed E; Janik J; Bookman MA; Rothenberg M; Smith J; Young RC; Ozols RF; VanderMolen L; Kohn E; Jacob JL
    J Clin Oncol; 1993 Nov; 11(11):2118-26. PubMed ID: 8229126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support.
    Fleming GF; Janisch L; Vogelzang NJ; Vokes EE; Ratain MJ
    Cancer; 1996 Jun; 77(11):2308-12. PubMed ID: 8635100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.